Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

0.7362 +0.0152 (+2.11%)

Streaming Delayed Price Updated: 2:39 PM EST, Feb 13, 2026 Add to My Watchlist

Price and Volume

Volume	50,814
Open	0.7198
Bid (Size)	0.7361 (500)
Ask (Size)	0.7495 (500)
Prev. Close	0.7210
Today's Range	0.7198 - 0.7586
52wk Range	0.6844 - 5.750
Shares Outstanding	417,247,333
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE

January 15, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th

January 15, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Performance

YTD	-16.2%	-16.2%
1 Month	-24.9%	-24.9%
3 Month	-46.3%	-46.3%
6 Month	-77.5%	-77.5%
1 Year	-74.2%	-74.2%

More News

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 15, 2026

From Schall Law

Via GlobeNewswire

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

January 14, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

January 14, 2026

From Berger Montague

Via GlobeNewswire

SKYE DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE

January 12, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

SKYE BIOSCIENCE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th

January 12, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 12, 2026

From Schall Law

Via GlobeNewswire

SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

January 09, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

January 09, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 08, 2026

From Schall Law

Via GlobeNewswire

SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. and Encourages Investors to Contact the Firm

January 06, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 05, 2026

From Schall Law

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

January 02, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 01, 2026

From Schall Law

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

December 29, 2025

From Schall Law

Via GlobeNewswire

NASDAQ: SKYE INVESTOR ALERT: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors of a January 16, 2026 Deadline

December 29, 2025

From Berger Montague

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

December 26, 2025

From Schall Law

Via GlobeNewswire

Which stocks are moving after the closing bell on Tuesday? ↗

December 23, 2025

Via Chartmill

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

December 23, 2025

From Schall Law

Via GlobeNewswire

SKYE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

December 20, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

December 19, 2025

From Schall Law

Via GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

December 16, 2025

From Schall Law

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, and Perrigo Investors to Contact the Firm Regarding their Rights

December 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing

December 15, 2025

From Berger Montague

Via GlobeNewswire

Frequently Asked Questions

Is Skye Bioscience, Inc. - Common Stock publicly traded?

Yes, Skye Bioscience, Inc. - Common Stock is publicly traded.

What exchange does Skye Bioscience, Inc. - Common Stock trade on?

Skye Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Skye Bioscience, Inc. - Common Stock?

The ticker symbol for Skye Bioscience, Inc. - Common Stock is SKYE on the Nasdaq Stock Market

What is the current price of Skye Bioscience, Inc. - Common Stock?

The current price of Skye Bioscience, Inc. - Common Stock is 0.7362

When was Skye Bioscience, Inc. - Common Stock last traded?

The last trade of Skye Bioscience, Inc. - Common Stock was at 02/13/26 02:39 PM ET

What is the market capitalization of Skye Bioscience, Inc. - Common Stock?

The market capitalization of Skye Bioscience, Inc. - Common Stock is 307.18M

How many shares of Skye Bioscience, Inc. - Common Stock are outstanding?

Skye Bioscience, Inc. - Common Stock has 307M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.